Abstract
Objective This study investigates how the SARS-CoV-2 transmission potential varied in North Dakota, South Dakota, Montana, Wyoming, and Idaho from March 2020 through January 2021.
Methods Time-varying reproduction numbers, Rt, of a 7-day-sliding-window and of non-overlapping-windows between policy changes were estimated utilizing the instantaneous reproduction number method. Linear regression was performed to evaluate if per-capita cumulative case-count varied across counties with different population size.
Results The median 7-day-sliding-window Rt estimates across the studied region varied between 1 and 1.25 during September through November 2020. Between November 13 and 18, Rt was reduced by 14.71% (95% credible interval, CrI, [14.41%, 14.99%]) in North Dakota following a mask mandate; Idaho saw a 1.93% (95% CrI [1.87%, 1.99%]) reduction and Montana saw a 9.63% (95% CrI [9.26%, 9.98%]) reduction following the tightening of restrictions. High-population counties had higher per-capita cumulative case-count in North Dakota at four time points (June 30, August 31, October 31, and December 31, 2020). In Idaho, North Dakota, and South Dakota, there was a positive correlation between population size and per-capita weekly incident case-count, adjusted for calendar time and social vulnerability index variables.
Conclusions Rt decreased after mask mandate during the region’s case-count spike suggested reduction in SARS-CoV-2 transmission.
Competing Interest Statement
ACS reports grants through her institution from the National Science Foundation, Cellex and Gilead Sciences. Via a subcontract with Einstein School of Medicine, she has received funding from the National Institutes of Health. She has received personal fees from, and served on an advisory board for, Gilead Sciences. She reports honoraria through third parties funded by Gilead, AbbVie, and Merck; personal fees from National Commission on Correctional Health Care, National Sheriff's Association, Harris County Sheriff's Office and California Department of Corrections and Rehabilitation; and travel expenses from bioLytical Sciences and Guardian. All other coauthors do not report any conflicts of interest.
Funding Statement
We did not receive any external funding for the research reported in this paper.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Georgia Southern University IRB determined a non-human subject status for this project (H20364) under the G8 exemption category as per Code of Federal Regulations Title 45 Part 46.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Xinyi Hua, Aubrey R. D. Kehoe, Joana Tome and Mina Motaghi serve as co-first authors.
Conflict of interest statement: ACS reports grants through her institution from the National Science Foundation, Cellex and Gilead Sciences. Via a subcontract with Einstein School of Medicine, she has received funding from the National Institutes of Health. She has received personal fees from, and served on an advisory board for, Gilead Sciences. She reports honoraria through third parties funded by Gilead, AbbVie, and Merck; personal fees from National Commission on Correctional Health Care, National Sheriff’s Association, Harris County Sheriff’s Office and California Department of Corrections and Rehabilitation; and travel expenses from bioLytical Sciences and Guardian.
Data Availability
All the data used in this paper are publicly available, aggregated, data. The cumulative confirmed case count data are available at the New York Times GitHub data repository. The 2019 county-level estimated population data are available from the US Census Bureau.
Abbreviation list
- COVID-19
- Coronavirus disease 2019
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- SVI
- Social Vulnerability Index
- U.S.
- United States
